Uncategorized

GeneCode has been named one of the TOP 5 best biotech companies to watch in 2024 by The Silicon Review! GeneCode research group led by Prof. Dr. Saarma is investigating the structure, biology, and therapeutic potential of neurotrophic factors. We specifically study the GDNF family neurotrophic factors and their receptors. Prof. Dr. Saarma’s exclusive interview is available…

The Life Sciences Review has nominated GeneCode Ltd. among TOP10 Drug Discovery and Development Solutions Provider in Europe 2023. GeneCode Reprint (PDF) GeneCode Ltd | Top Drug Discovery and Development Solutions Company in Europe-2023 (lifesciencesreview.com)

GeneCode’s R&D project has received tremendous backing from Enterprise Estonia, and we are grateful for their critical support. In collaboration with them, we have taken time to reflect on our journey with them and Argobio and look ahead to the future. https://investinestonia.com/follow-the-science-end-up-in-estonia/

European Innovation Council (EIC) Accelerator is providing € 16 million to support the development of a drug and treatment to slow the progression in Parkinson’s disease. The funding to GeneCode for the Kevad Bio project developed in collaboration with Argobio is split into a € 1.7 million grant and € 14.3 million in equity investments. This…

Launch of WHO’s Parkinson disease technical brief. Globally, the prevalence of Parkinson disease (PD) has doubled in the past 25 years with global estimates in 2019 showing over 8.5 million individuals living with PD. Disability and death due to PD are increasing faster than for any other neurological disorder. Current estimates suggest that, in 2019,…

Excellent start to the year 2022. GeneCode to Accelerate GDNF Mimetics program on Parkinson’s Disease with 2 million euro R&D Grant from Enterprise Estonia: PR_Genecode_EAS_EN_13.01.2022

We are very honored to share the news of the GeneCode and Argobio Partners on Parkinson’s Disease in Argobio’s First Announced Research Agreement. Read more: https://www.argobiostudio.com/en/news/argobio-and-genecode-partner-on-parkinsons-disease-in-argobios-first-announced-research-agreement#news

GeneCode ordered a Freedom to Operate search on a group of chemical compounds from international patent and trademark attorneys. (Project period: 07.04.2021-08.08.2021). According to the final analysis, the patents were discovered alive and are not relevant concerning GeneCode’s freedom to operate. The project was partly financed by the European Regional Development Fund with 1760 euros.

Current Parkinson’s Disease treatments only relieve symptoms without halting the progression of the disease, and their use is complicated by severe adverse effects emerging as the disease progresses. Therefore, there is an urgent need for new therapies for PD management. We developed a small molecule compound, BT13, targeting receptor tyrosine kinase RET. Research article “GDNF…

Digital RESI Europe. GeneCode participated in the Virtual Partnering Conferences (23-25 March 2020). The goal of the partnering event was to match the fundraising CEOs and the scientist-entrepreneurs with investors and strategic partners that are a fit for their stage of development and product set. https://resiconference.com/